B cells from MS patients exhibit higher surface expression of HLA-DR, CD40, and CD80/86 than healthy donor (HC) derived B cells suggesting that B cells may be highly poised towards antigen presentation in the MS patients (4) with CD40, CD80, and CD86, also contributing towards significant genetic risk (5). This evidence concerns the gene CD86 and myeloid sarcoma.